• DNDi logo
  • COVID-19
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Hepatitis C
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • COVID-19
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Hepatitis C
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Efforts to register new hepatitis C treatment in Malaysia receive support from Pharmaniaga

Home > Press releases

Efforts to register new hepatitis C treatment in Malaysia receive support from Pharmaniaga

Kuala Lumpur, Malaysia / Geneva, Switzerland — 25 Nov 2019
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

The non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) is pleased to announce a contribution of USD 2.2 million (9.2 million Malaysian Ringgit) from Malaysian pharmaceutical company, Pharmaniaga, to support the registration of a new treatment combination for people living with the hepatitis C virus (HCV) in Malaysia.

The contribution by Pharmaniaga will support the registration of a new combination therapy using ravidasvir, which is being evaluated in combination with sofosbuvir in clinical trials in Malaysia co-sponsored by DNDi and the Malaysian Ministry of Health.

‘This support from Pharmaniaga will support the delivery of a new direct-acting antiviral treatment for hepatitis C. It will increase treatment options and facilitate access to medicines and the fruits of innovation in countries where the price of HCV is still a barrier,’ said Jean-Michel Piedagnel, Director of DNDi, South-East Asia.  

HCV is a silent epidemic, as the huge majority of those infected are not aware of their status, show no symptoms of the disease, and therefore do not seek treatment. In recent years, drug prices have fallen considerably, but not enough for countries to roll out treatment widely or test-and-treat strategies that could lead towards elimination of the disease as a public health problem.

An estimated 400,000 people are living with hepatitis C in Malaysia. The Government of Malaysia has committed to providing HCV screening, diagnosis and treatment free of charge through the public health system. The Ministry of Health, in collaboration with the Foundation for Innovative New Diagnostics (FIND) and DNDi, is actively decentralizing hepatitis C treatment in order to scale up its efforts to treat more patients.

‘We see this contribution as affirmative action where we continue to work together to prevent, test, and treat hepatitis C. Pharmaniaga remains optimistic that as a nation, we will succeed in eliminating hepatitis C in Malaysia by 2030. We are also committed to finding the #missingmillions and providing cheaper alternative to treatment,’ said Dato’ Farshila Emran, Managing Director of Pharmaniaga.

DNDi and its industrial partners will pursue registration of ravidasvir in Malaysia in 2020.

About hepatitis C

HCV is one of the world’s most common infectious diseases, usually contracted through unsafe healthcare and injection drug use. Globally, more than 71 million people are chronically infected, over 80% of whom live in low- and middle-income countries – but only one in five people know they have the disease. Around 400,000 people die every year, and the mortality rate is increasing, making it a global health priority: the World Health Organization (WHO) has set an ambitious target of viral hepatitis elimination by 2030. In Malaysia, HCV disease burden is high and predicted to rise steeply over the coming decades, leading to a projected 63,900 HCV-related deaths by 2039.

About DNDi

The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit R&D organization working to deliver new treatments for neglected patients, in particular for sleeping sickness, Chagas disease, leishmaniasis, filaria, mycetoma, paediatric HIV/AIDS, and hepatitis C virus (HCV). DNDi’s ambition is to enable access to HCV treatment, through the development and registration of affordable, safe, and efficacious pan-genotypic direct-acting antivirals (DAAs), and by supporting policy change and political will to remove barriers to access to DAAs globally. www.dndi.org

Media contact

DNDi South East Asia
Molly Jagpal
+60 (0)12 546 8362
mjagpal@dndi.org

DNDi Geneva
media@dndi.org

Photo credit: Kitjapat Natthapisut-DNDi

Funding Hepatitis C

Read, watch, share

HAT Platform newsletter 2021 thumbnail
Publications
22 Feb 2021

HAT Platform Newsletter No. 21

Girl being examined by a doctor
News
1 Feb 2021

Innovation to reach the destination: World NTD Day 2021

Father walking with a cane and holding his son's hand
Stories
28 Jan 2021

The innovation neglected patients deserve

Laboratory staff working
Viewpoints
28 Jan 2021

WHO 2030 NTDs Roadmap: how science and partnerships can support the fight to end neglected diseases

Viewpoints
18 Dec 2020

Gender and R&D: DNDi effectively mobilized

Doctor walking in front of the Hopital Saint Joseph
Press releases
24 Nov 2020

Largest clinical trial in Africa to treat COVID-19 cases before they become severe is launched in 13 countries

Dr Bernard Pécoul
Press releases
12 Nov 2020

Thailand’s Prince Mahidol Award honours Dr Bernard Pécoul, Founder of DNDi, for his service to public health

Healthcare worker with a patient in hospital setting
News
10 Nov 2020

Siriraj Institute of Clinical Research and DNDi to collaborate on initiatives to address the gaps in R&D and access to medicines

VIEW ALL

Help neglected patients

To date, we have delivered eight new treatments, saving millions of lives.

We’re halfway to our goal of delivering 16-18 treatments by 2023. You can help us get there. 

GIVE NOW
DNDi logo
Facebook-f Twitter Instagram Linkedin-in Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By continuing to browse our website, you are agreeing to our use of cookies.CLOSECOOKIE POLICY